We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Infinity Pharmaceuticals Inc | NASDAQ:INFI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0322 | 0.0321 | 0.0348 | 0 | 01:00:00 |
Filed by the Registrant ☒
|
Filed by a party other than the Registrant ☐
|
☐
|
Preliminary Proxy Statement
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☐
|
Definitive Proxy Statement
|
☒
|
Definitive Additional Materials
|
☐
|
Soliciting Material Pursuant to §240.14a-12
|
Infinity Pharmaceuticals, Inc.
|
☒
|
No fee required.
|
☐
|
Fee paid previously with preliminary materials.
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
◾ |
A robust and differentiated pipeline of three promising clinical-stage oncology drug candidates with initial clinical data on all 3 programs
expected by the end of 2024 that we believe position the company for multiple potential near- and long-term value creation events.
|
◾ |
Approximately $100 million of cash and equivalents projected at the time of the closing that is expected
to fund operations through mid-2025, with clinical milestones expected over the next 12 to 24 months.
|
◾ |
An experienced management team focused on clinical development and operational excellence.
|
◾ |
Eganelisib, an oral immuno-oncology macrophage reprogramming PI3K-gamma inhibitor candidate, which is planned to be evaluated in combination
with the PD-1 targeted checkpoint inhibitor pembrolizumab (KEYTRUDA®) in patients with first-line recurrent/metastatic head and neck squamous cell
carcinoma (HNSCC);
|
◾ |
Voruciclib, an oral CDK9 inhibitor, currently being studied in combination with venetoclax (VENCLEXTA®) in patients with hematologic malignancies; and
|
◾ |
ME-344, a novel tumor selective mitochondrial inhibitor targeting the OXPHOS pathway, to be evaluated in combination with bevacizumab (AVASTIN®) in patients with relapsed colorectal cancer.
|
1 Year Infinity Pharmaceuticals Chart |
1 Month Infinity Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions